A detailed history of Wealthfront Advisers LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Wealthfront Advisers LLC holds 39,200 shares of VRTX stock, worth $15.9 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares
39,200
Previous 39,690 1.23%
Holding current value
$15.9 Million
Previous $18.6 Million 2.0%
% of portfolio
0.06%
Previous 0.06%

Shares

24 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$460.0 - $505.78 $225,400 - $247,832
-490 Reduced 1.23%
39,200 $18.2 Million
Q2 2024

Aug 14, 2024

SELL
$392.81 - $485.53 $277,716 - $343,269
-707 Reduced 1.75%
39,690 $18.6 Million
Q1 2024

Apr 19, 2024

SELL
$407.69 - $446.08 $107,222 - $117,319
-263 Reduced 0.65%
40,397 $16.9 Million
Q4 2023

Feb 09, 2024

SELL
$343.0 - $410.68 $207,515 - $248,461
-605 Reduced 1.47%
40,660 $16.5 Million
Q3 2023

Nov 01, 2023

SELL
$338.18 - $362.46 $120,392 - $129,035
-356 Reduced 0.86%
41,265 $14.3 Million
Q2 2023

Aug 07, 2023

BUY
$314.42 - $351.91 $547,719 - $613,027
1,742 Added 4.37%
41,621 $14.6 Million
Q1 2023

Apr 28, 2023

BUY
$283.23 - $323.1 $1.38 Million - $1.58 Million
4,883 Added 13.95%
39,879 $12.6 Million
Q4 2022

Feb 10, 2023

SELL
$285.76 - $321.48 $1.01 Million - $1.13 Million
-3,525 Reduced 9.15%
34,996 $10.1 Million
Q3 2022

Nov 14, 2022

BUY
$273.83 - $305.53 $1.26 Million - $1.4 Million
4,596 Added 13.55%
38,521 $11.2 Million
Q2 2022

Jul 20, 2022

BUY
$234.96 - $292.55 $4.36 Million - $5.43 Million
18,566 Added 120.88%
33,925 $9.56 Million
Q1 2022

May 16, 2022

BUY
$221.42 - $260.97 $1.82 Million - $2.15 Million
8,236 Added 115.63%
15,359 $4.01 Million
Q4 2021

Jan 21, 2022

BUY
$177.01 - $223.45 $252,239 - $318,416
1,425 Added 25.01%
7,123 $1.56 Million
Q3 2021

Nov 15, 2021

BUY
$181.39 - $202.99 $4,716 - $5,277
26 Added 0.46%
5,698 $1.03 Million
Q2 2021

Aug 16, 2021

SELL
$187.49 - $221.1 $725,398 - $855,435
-3,869 Reduced 40.55%
5,672 $1.14 Million
Q1 2021

May 14, 2021

BUY
$207.02 - $241.31 $260,845 - $304,050
1,260 Added 15.22%
9,541 $2.05 Million
Q4 2020

Feb 16, 2021

SELL
$207.01 - $276.09 $192,519 - $256,763
-930 Reduced 10.1%
8,281 $1.96 Million
Q3 2020

Nov 16, 2020

SELL
$255.65 - $303.1 $1,278 - $1,515
-5 Reduced 0.05%
9,211 $2.51 Million
Q2 2020

Aug 14, 2020

BUY
$225.48 - $295.8 $209,696 - $275,094
930 Added 11.22%
9,216 $2.68 Million
Q1 2020

May 15, 2020

BUY
$199.77 - $247.81 $226,339 - $280,768
1,133 Added 15.84%
8,286 $1.97 Million
Q4 2019

Jan 21, 2020

BUY
$166.71 - $223.91 $99,525 - $133,674
597 Added 9.11%
7,153 $1.57 Million
Q3 2019

Oct 15, 2019

SELL
$166.23 - $187.09 $105,057 - $118,240
-632 Reduced 8.79%
6,556 $1.11 Million
Q2 2019

Aug 13, 2019

BUY
$164.61 - $190.37 $35,061 - $40,548
213 Added 3.05%
7,188 $1.32 Million
Q1 2019

May 13, 2019

BUY
$163.73 - $194.7 $22,103 - $26,284
135 Added 1.97%
6,975 $1.28 Million
Q4 2018

Feb 14, 2019

BUY
$151.91 - $192.21 $1.04 Million - $1.31 Million
6,840 New
6,840 $1.13 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $104B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Wealthfront Advisers LLC Portfolio

Follow Wealthfront Advisers LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wealthfront Advisers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Wealthfront Advisers LLC with notifications on news.